MoonLake Immunotherapeutics (MLTX) Cash & Current Investments (2020 - 2026)

MoonLake Immunotherapeutics' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $357.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 25.45% year-over-year to $357.9 million; the TTM figure through Mar 2026 stood at $357.9 million (down 25.45% YoY), while the FY2025 annual figure was $394.0 million, down 12.07% from the prior year.
• Cash & Current Investments was $357.9 million for Q1 2026 at MoonLake Immunotherapeutics, down from $394.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $547.1 million in Q1 2024 to a low of $63.0 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $367.2 million across 5 years, with a median of $436.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments jumped 8533.99% in 2022, then sank 37.61% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $72.1 million in 2022, then jumped by 608.6% to $511.0 million in 2023, then dropped by 12.32% to $448.0 million in 2024, then decreased by 12.07% to $394.0 million in 2025, then retreated by 9.15% to $357.9 million in 2026.
• The last three Cash & Current Investments figures came in at $357.9 million (Q1 2026), $394.0 million (Q4 2025), and $380.5 million (Q3 2025), per Business Quant data.